Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis

Published:2024-07 Issue: Volume: Page:
ISSN:0002-9629
Container-title:The American Journal of the Medical Sciences
language:en
Short-container-title:The American Journal of the Medical Sciences

Author:

Tuersun Adili,Hou Guanxin,Cheng Gang

Publisher

Elsevier BV

Reference26 articles.

1. Type 2 diabetes;Ahmad;Lancet,2022

2. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 Inhibitors in Type 2 diabetes mellitus: a systematic review and meta-analysis;Li;Front Pharmacol,2022

3. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis;Liu;BMJ-British Med J,2017

4. Positioning SGLT2 Inhibitors/Incretin-based therapies in the treatment algorithm;Wilding;Diabetes Care,2016

5. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes;Busch;Postgrad Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP